Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
- Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in
Healthy Volunteers, Transitioning to a Clinical-Stage Company
- Presented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy Program at the
Society for Immunotherapyof Cancer’s ( SITC) 33rd Annual Meeting
- Announced Strategic Collaboration with
Gilead Sciencesto Discover and Develop Highly Specific Inhibitors of TGFβ activation for the Treatment of Fibrotic Diseases
- Completed Initial Public Offering Raising Approximately
$86 millionin Gross Proceeds
Key 2018 Accomplishments
- Completed initial public offering and raised approximately
$86 millionin gross proceeds.
- Entered into a strategic fibrosis-focused collaboration with
Gilead Sciences, Inc.to discover and develop highly specific inhibitors of TGFβ activation ( $80 millionreceived upfront and eligible for up to an additional $1,450 millionin potential milestone payments).
- Transitioned to a clinical-stage company with the initiation of a Phase 1 clinical trial of SRK-015 in healthy volunteers.
- Published preclinical data on the therapeutic benefit of inhibiting myostatin activation in mouse models of Spinal Muscular Atrophy (SMA) in peer-reviewed journal Human Molecular Genetics.
- Received Orphan Drug Designation from the
U.S. Food and Drug Administration( FDA) and Orphan Medicinal Product Designation from the European Commission(EC) for SRK-015 for the treatment of SMA.
- Presented compelling preclinical data that demonstrate SRK-181-mIgG1 (murine version of SRK-181), a highly specific TGFβ1 inhibitor, can render resistant solid tumors vulnerable to PD1 blockade.
- Progressed antibody platform for neuromuscular disorders, cancer immunotherapy, fibrosis, and anemias.
“2018 was a year of remarkable progress with our platform and for establishing a strong foundation as we transitioned to a public company,” said Nagesh Mahanthappa, Ph.D, President and CEO of
R&D Highlights and Upcoming Milestones
- Presented Interim Results from Phase 1 Clinical Trial of SRK-015 in
Healthy Volunteers. In February 2019, Scholar Rockpresented positive interim results from the Phase 1 clinical trial of SRK-015, a highly specific inhibitor of myostatin activation, which was observed to be well tolerated with no dose limiting toxicities identified up to the highest evaluated dose of 30 mg/kg. Pharmacodynamic data, measuring serum concentrations of latent myostatin, demonstrated robust and sustained target engagement, providing initial proof-of-mechanism for this unique therapeutic approach. Collectively, the favorable interim safety and tolerability, pharmacodynamic, and pharmacokinetic data supported the advancement of SRK-015 to a Phase 2 proof-of-concept clinical trial in patients with SMA.
- Initiating Phase 2 Proof-of-Concept Trial for SRK-015 in SMA in First Quarter 2019. Scholar Rock is initiating a Phase 2 proof-of-concept trial to assess the safety and efficacy of SRK-015. The trial will consist of three non-overlapping cohorts, each evaluating a distinct subpopulation of patients with Type 2 and Type 3 SMA and all patients will receive SRK-015 dosed once every four weeks either as a monotherapy or in conjunction with an approved survival motor neuron (SMN) upregulator therapy. The primary efficacy endpoints will measure motor function through clinically meaningful outcome measures validated in SMA, such as the Hammersmith Functional Motor Scale Expanded (HFMSE) in non-ambulatory SMA and the Revised Hammersmith Scale (RHS) in ambulatory SMA, over a 12-month treatment period.
Scholar Rockplans to provide additional details on the Phase 2 trial design at the time of initiating patient dosing in the second quarter of 2019. Interim safety and efficacy results for a subset of patients in each cohort with at least six months of treatment exposure are expected in the first half of 2020.
- Plan to Identify Second Indication for SRK-015 in 2020.
Scholar Rockcontinues to see multiple potential opportunities for which SRK-015 could offer clinical benefit and is assessing additional potential clinical settings in which the selective inhibition of the activation of myostatin may offer therapeutic benefit.
- Nominated SRK-181 as Cancer Immunotherapy Product Candidate. In
March 2019, Scholar Rockselected SRK-181, a highly specific inhibitor of TGFβ1 activation, as the first product candidate in its TGFβ1 cancer immunotherapy program based on the strength of preclinical data and human translational insights. SRK-181 is being developed for the treatment of tumors resistant to checkpoint blockade therapies (CBTs), such as anti-PD(L)1 antibodies. Scholar Rockplans to initiate a Phase 1 trial in patients with solid tumors in mid-2020.
- Additional SRK-181-mIgG1 Preclinical Data to be Presented at Upcoming AACR Annual Meeting.
Scholar Rockwill present additional preclinical data from multiple syngeneic mouse models of primary checkpoint resistance at the 2019 American Association for Cancer Research(AACR) Annual Meeting being held March 29-April 3, 2019. These studies demonstrate that co-administration of SRK-181-mIgG1 (murine version of SRK-181) with an anti-PD1 antibody permits effector T cell infiltration and expansion into the tumor microenvironment, resulting in tumor regression or control as well as significant survival benefit, while minimizing toxicities traditionally associated with pan-TGFβ inhibitors.
Full Year 2018 Financial Results
For the year ended
- Research and development expense was
$36.3 millionfor the year ended December 31, 2018compared to $19.9 millionfor the year ended December 31, 2017. The increase year-over-year in both periods reflect development and manufacturing costs associated with lead product candidate, SRK-015, research costs associated with preclinical studies, as well as increased personnel-related costs to support continued progress with the pipeline.
- General and administrative expense was
$14.4 millionfor the year ended December 31, 2018compared to $5.1 millionfor the year ended December 31, 2017. The increase year-over-year was primarily attributable to increased headcount and higher professional and consulting fees associated with the IPO and collaboration with Gilead, as well as ongoing business activities and operations as a public company.
“We established a strong financial foundation in 2018 with contributions from our successful IPO and our strategic fibrosis collaboration with Gilead,” said
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect.
Scholar Rock® is a registered trademark of
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its strategy, progress and timing of its Phase 1 and Phase 2 clinical trials for SRK-015, its product candidate selection and development timing, including its plans and timing for developing SRK-181 and timing for identifying a second disease indication for SRK-015, and the ability of any product candidate to perform in humans in a manner consistent with nonclinical or preclinical study data. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock’s current and potential future collaborations, including its collaboration with Gilead, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, and Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended
|Scholar Rock Holding Corporation|
|Condensed Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Years Ended December 31|
|Research and development||$||36,310||$||19,944|
|General and administrative||14,382||5,085|
|Total operating expenses||50,692||25,029|
|Loss from operations||(50,692||)||(25,029||)|
|Interest income, net||1,422||44|
|Other expense, net||(56||)||(10||)|
|Total other income (expense)||1,366||34|
|Net loss per share, basic and diluted||$||(3.15||)||$||(15.30||)|
|Weighted-average common shares outstanding - basic and diluted||15,655,293||1,634,100|
|Scholar Rock Holding Corporation|
|Condensed Consolidated Balance Sheets|
|December 31, 2018||December 31, 2017|
|Cash, cash equivalents and marketable securities||$||175,645||$||57,959|
|Other current assets||2,296||$||1,242|
|Total current assets||177,941||59,201|
|Liabilities and Stockholders' Equity|
|Convertible preferred stock||—||109,232|
|Total stockholders' equity (deficit)||106,623||(53,522||)|
|Total liabilities, convertible preferred stock and stockholders' equity (deficit)||$||181,336||$||61,637|
Scholar Rock Contact: Investors/Media
Catherine Huchu@scholarrock.com 917-601-1649 Media Contact: The Yates Network Kathryn Morriskathryn@theyatesnetwork.com 914-204-6412
Source: Scholar Rock